• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10
    • Buyers' Guide
    • Events
    • Microsites
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10
  • Buyers' Guide
  • Events
  • Microsites
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    Top Features
    Instrumentation Innovations: A Review of Instrument Manufacturing

    The Total Package: Packaging and Sterilization for Orthopedics

    Helping Nature Take Its Course: A Biologics Breakdown

    Making the Grade: Orthopedic Materials Spotlight

    Mending Mishaps: A Trauma Technology Overview
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    Orthopedic Innovators
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    Lincotek Medical Expands Coatings and Additive Capacity

    Spinal Elements Relaunches the Luna XD and Orbit Systems

    Coronavirus Triggers Double-Digit Revenue Dropoff at Smith+Nephew

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant

    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    Medtech Matters: FDA’s Ambiguity on Hyaluronic Acid

    Orthopedic Innovators: Optimizing the Contract Services Experience

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System

    First Implantation of CTL Amedica's Minimally Invasive Flex Tower

    NuVasive Nabs Simplify Medical for $150M
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Orthopedic Solutions from Man’s Best Friend

    The FDA’s Flip-Flop on Hyaluronic Acid

    HSS, Zimmer Biomet's Solution for the Episode of Orthopedic Care

    Rising to the Challenge: Q&A with AAOS Second VP Dr. Savoie

    Teleconferencing in the OR
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Sayan Orthopaedics Ltd.

    Donatelle

    Tiodize

    Master Bond Inc.

    ARCH Medical Solutions
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Columns

    An FDA Regulatory Perspective on Bone Grafts

    There are various bone grafts with different composition, source, mechanical strength, and functional biological mechanisms.

    An FDA Regulatory Perspective on Bone Grafts
    Related CONTENT
    • FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    • Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    • SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    • Nexus Spine Announces Availability of Spine Surgery Implants
    • Washington University Professor Honored for Functional Cartilage Engineering Research
    Mehdi Kazemzadeh-Narbat, Ph.D., Senior Associate, Regulatory Affairs, MCRA LLC02.08.21
    After trauma, lost or damaged bone tissue can naturally remodel and repair fractures and small noncritical size bone defects. But, large bone defects (critical size) created by severe trauma or tissue resection due to cancer or infection cannot heal on their own without help from therapeutic aids or materials designed to encourage bone regeneration. A bone graft acts as a filler or scaffold for new bone growth, and bone grafting is a surgical procedure that uses bone graft to repair and rebuild diseased or damaged bones. Approximately 500,000, and more than 2 million bone graft procedures are performed annually in the U.S. and worldwide respectively.1,2 Market research3 estimates the global bone graft and substitutes sector to have been worth $2.68 billion in 2019 and will grow 5.1 percent annually through 2027.

    There are various bone grafts with different composition, source, mechanical strength, and functional biological mechanisms. Each type of bone graft has its own unique advantages and disadvantages regarding biological properties and bone healing, which make them suitable for numerous orthopedic, craniomaxillofacial, and dental indications. Some of a bone graft’s biological properties are summarized below.2
    • Osteoconduction: The ability to promote migration, attachment, and growth of osteoblastic cells onto the bone graft.
    • Osteoinduction: The ability to recruit and stimulate differentiation of immature (osteoprogenitor) cells toward an osteoblast lineage.
    • Bioactive: The ability to induce the formation of a direct chemical bond with surrounding tissue by eliciting a biological response at the interface.
    • Osteointegration: A direct structural and functional connection between ordered living bone and a load-carrying implant surface.

    Types of Bone Grafts2,4,5
    Autografts: Considered the “gold standard” in bone substitution, autogenous bones are those that are harvested from bones of the same individual (the iliac crest, fibula, ribs, mandible, chin, or skull).

    Autogenous cancellous bone also can be obtained from the intramedullary canal. Autogenous bones are osteoconductive, osteoinductive, and contain growth factors and osteogenic cells with no associated immune or infective-related risks. However, they have limited availability and procurement morbidity, and they require a second surgery, which can result in donor site pain, infection, fracture, and other complications such as neurovascular injury and cosmetic deformity.

    Allografts: These bone substitutes are derived from another living human or cadaver and must be processed within a bone tissue bank. Allografts are osteoconductive but since they undergo tissue processing (e.g., endotoxin [pyrogenic]/viral inactivation), freeze drying, and sterilization, they lack important growth factors and proteins found in a healthy bone, and therefore have little or no osteoinductive property. They are available in large quantities and are less invasive than autografts with less surgery time and minimum recovery and complications. Nevertheless, allografts have lower mechanical strength than natural bone, are more slowly incorporated, and can precipitate immunogenic reaction, as well as transfer disease. Demineralized bone matrix (DBM) can be obtained from allograft bones by removing the mineralized component using acid extraction. The resulting matrix is predominantly type I collagen in addition to several growth factors including bone morphogenetic proteins (BMPs) and can be used as osteoconductive and osteoinductive bone graft extenders.

    Xenografts: These bone substitutes are taken from a non-human donor such as bovine or porcine. Xenografts must be anorganic (as a calcified matrix), meaning all remnants of the donor animal must be removed to minimize antigenic responses. Therefore, they undergo copious washing, endotoxin (pyrogenic)/viral inactivation, and heat treatment processes to remove, grease, lipids, proteins, and collagens. Xenografts are osteoconductive, easily available, economical, and have good mechanical properties. However, they are not osteoinductive, and have limited validation in clinical orthopedic practice.

    Synthetic bone grafts: These grafts are produced from different biomaterials such as calcium phosphates including hydroxyapatite or tricalcium phosphate (TCP), bioactive glasses, composites of bioinorganics such as magnesium, silicon, and strontium ions into TCP, and composite of polymers such as collagen, PLA, PGA, PLGA, and PCL with ceramics. They are available in many forms (blocks, granules, cements, and injectable kits). They are associated with less pain, operating time, blood loss, and complications compared with autografts. Synthetic bone grafts are usually osteoconductive but have the lowest osteoinductivity of any other grafts. They are not as widely accepted as other types of bone grafts and still lack significant market penetration due to the lack of clinical evidence regarding their efficacy.

    Cellular-based grafts: Cellular bone matrices (CBMs) are allogenic or synthetic bone grafts containing live mesenchymal stem cells (MSCs). In addition to their osteoconductive property, these grafts promote osteogenesis, as isolated MSCs are the osteogenic cells that can differentiate into the osteoblasts required for bone repair, remodeling, and maturation. CBMs are estimated to comprise more than 17 percent of all bone grafts. However, further in vivo and clinical investigation of their potential is required; based on literature, for example, their efficacy in spinal fusion surgery remains highly inconclusive.

    Regulatory Considerations
    FDA classifies a product as a drug, device, biological product, or combination product.6 A combination product is composed of any combination of a drug and device; a biological product and device; a drug and biological product; or a drug, device, and biological product.7

    FDA has published two special controls guidance documents related to bone grafts,8,9 which comply with the special controls proposed in 21 CRF §888.3045, and 21 CFR §872.3930.10,11 According to these special controls, bone grafts intended to fill bony voids or gaps caused by trauma or surgery that are not intrinsic to the bony structure’s stability, or those aiming to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region are considered “Class II devices.” They therefore are subject to premarket notification procedures and special controls, and when combined with general controls, are sufficient to provide reasonable assurance of the bone graft’s safety and effectiveness.

    Bone grafts containing drugs are considered a therapeutic biologic and are regulated as Class III devices, requiring a PMA. According to the FDA, human demineralized bone matrix (DBM), when combined with other components (sodium hyaluronate, glycerol, or calcium phosphate) for easier handling and thus becoming a putty or paste, are regulated under the device provisions.12 Any other novel materials, new indications for use, or manufacturing process that is not addressed in any FDA recognized conformance standard or FDA guidance document may raise different types of safety and effectiveness questions. In that case companies should consider submitting a pre-submission (Q-submission) for feedback on the type of information needed.13

    FDA guidance14 states that cultured cells combined with other materials (i.e., bone grafts) are considered combination products and may be regulated as devices or biological products. If the classification of a product as a drug, device, biological product, or combination product is unclear or in dispute, a Requests for Designation (RFD) may be requested to obtain a formal determination of a combination product’s primary mode of action as well as assignment of the lead agency center for the product’s premarket review and regulation within 60 days.6 If it is determined the cells contribute a primary mode of action for the combination product, the Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapies provides the administrative and review leads. In this case, the CDRH/OPEQ/OHT6 provides consult reviews for CBER.

    Bone grafts reviewed under 510(k) should demonstrate sufficient performance data to support their indications for use and labeling including bench testing and animal (in vivo) study.8,9 Performance data should be conducted on the final, sterilized bone grafts, with a legally marketed predicate device to demonstrate substantial equivalence. Bench testing should cover the physical properties, chemical composition, and mechanical characteristics of bone grafts. FDA guidance indicates that bone grafts containing animal-derived materials such as collagen should provide sufficient information about the animal material and viral inactivation validation.15,16 Also, any claim regarding superiority, or biological properties including osteoinduction, or bioactivity should be supported by performance data. In addition to bench testing and in-vitro testing, the agency usually requests a controlled in vivo study to demonstrate the substantial equivalence of bone grafts compared to similar safety and effectiveness predicates. There are special considerations for bone grafts containing nanomaterials.17,18

    All types of bone grafts should demonstrate biocompatibility in accordance with ISO 10993-1. According to attachment A of FDA’s guidance on ISO-10993-1,19 bone grafting materials are implant devices in contact with tissue/bone/dentin for a permanent contact duration. Therefore, the following biocompatibility endpoints should be addressed for bone grafts in compliance with Good Laboratory Practice:
    • Cytotoxicity (per ISO 10993-5)
    • Sensitization (per ISO 10993-10)
    • Irritation or intracutaneous reactivity (per ISO 10993-10)
    • Acute systemic toxicity (per ISO 10993-11)
    • Pyrogenicity
    • Lot-release Limulus Amoebocyte Lysate (LAL) Test;20 and
    • Rabbit Pyrogen Test (per ISO 10993-11)
    • Subacute/Subchronic Toxicity (per ISO 10993-11)
    • Genotoxicity (per ISO 10993-5)
    • Implantation (with histology of the surrounding tissue per ISO 10993-6)
    • Chronic toxicity (per ISO 10993-11)
    • Carcinogenicity (per ISO 10993-5)
    According to FDA guidance, sponsors may leverage information from existing marketing applications to support a rationale that bone graft biocompatibility has been established. If the sponsor can prove the raw materials, manufacturing process, sterilization, and packaging of the bone graft is identical to another cleared predicate in the U.S. market, no additional biocompatibility testing is necessary.

    Moreover, the agency accepts the use of chemical characterization/risk assessment approach (per ISO 10993-18) in lieu of biological testing to evaluate the systemic as well as genotoxicity and carcinogenicity risks.

    While the agency does not usually request for clinical studies for 510(k) bone grafts, clinical trials/evidence may be requested when the bone graft has different technology, indications for use, or formulation compared to predicates, or when performance testing raises concerns that warrant clinical evaluation. Amongst different types of bone grafts, those that contain drugs are regulated as Class III devices, requiring a PMA and a clinical trial. Moreover, resorbable bone void fillers containing human DBM are generally considered significant risk devices, and require a conduct of clinical study.21 

    References
    1. www.ncbi.nlm.nih.gov/pmc/articles/PMC6417250/
    2. pubmed.ncbi.nlm.nih.gov/24865980/
    3. bit.ly/2NvitHh
    4. pubmed.ncbi.nlm.nih.gov/30623986/
    5. pubmed.ncbi.nlm.nih.gov/22500826/
    6. bit.ly/2Mh1sjc
    7. bit.ly/3685kue
    8. www.fda.gov/media/71406/download
    9. bit.ly/2Y8mQtI
    10. FDA, Device Classification Panels, (2018)
    11. FDA, Product Classification Database
    12. bit.ly/2LVFanu
    13. bit.ly/3peaE6S
    14. bit.ly/3sROwRJ
    15. bit.ly/2KKQzGg
    16. bit.ly/3od0q58
    17. bit.ly/2Mkw3wE
    18. bit.ly/3cgyds7
    19. bit.ly/3sRD3l6
    20. bit.ly/3sQY9An
    21. bit.ly/39QNJIc


    Prior to joining MCRA, Mehdi worked in the FDA’s Center for Devices and Radiological Health as a pre-market and post-market lead reviewer of orthopedic and dental devices. He is a biomedical engineer with five years of FDA experience in medical device regulation, and is a consultant for biocompatibility, animal study, and antimicrobial-associated devices. At MCRA, Mehdi provides guidance on regulatory strategies and submissions development across various therapies, including orthopedic, general hospital, cardiovascular, neurologic, and as well as antimicrobial devices, drugs, and combination products. Mehdi received his Ph.D. in biomedical engineering from the University of British Columbia, Vancouver. He also received his MS and BS in biomedical engineering from Iran.
    Suggested For You
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    Pandemic Pain: NuVasive Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Nexus Spine Announces Availability of Spine Surgery Implants Nexus Spine Announces Availability of Spine Surgery Implants
    Washington University Professor Honored for Functional Cartilage Engineering Research Washington University Professor Honored for Functional Cartilage Engineering Research
    Sports Injury Doctor Recognized for Research on Epidemiology, Severe Athletic Injuries Sports Injury Doctor Recognized for Research on Epidemiology, Severe Athletic Injuries
    Acquisitions Set to Propel Global Orthopedics Market to $64 Billion by 2025 Acquisitions Set to Propel Global Orthopedics Market to $64 Billion by 2025
    Neo Medical Buys TriOs Medical; Appoints New U.S. President Neo Medical Buys TriOs Medical; Appoints New U.S. President

    Related Columns

    • Striving to Attain a Gain on the Pain

      Striving to Attain a Gain on the Pain

      A growing number of orthopedic patients are wrestling with fear, perhaps fueled in part by variant virus strains believed to be more contagious.
      Michael Barbella, Managing Editor 02.08.21

    • Rethink Your Orthopedic ASC Strategy, Part 1

      Rethink Your Orthopedic ASC Strategy, Part 1

      ASCs have adopted a strategy to focus on predictable, low-risk procedures with lower complication rates in an out-of-hospital setting.
      Maria Shepherd, President and Founder, Medi-Vantage 02.08.21

    • Pandemic-Level Playing Field: How COVID-19 Made Space for Progress

      Pandemic-Level Playing Field: How COVID-19 Made Space for Progress

      Pandemic restrictions may have diminished certain advantages large companies hold over small and mid-sized competitors.
      Dawn A. Lissy, Founder & President, Empirical 02.08.21


    • Tips for Reigniting Your MDR/IVDR Preparation

      Tips for Reigniting Your MDR/IVDR Preparation

      To get the MDR/IVDR preparation ball rolling again, here are four processes to help refocus on achieving compliance with the updated regulations.
      Nicolle Cannon, Founder and CEO, Cannon Quality Group LLC 02.08.21

    • Packaging & Sterilization
      Building a More Transparent Healthcare Supply Chain with UDI

      Building a More Transparent Healthcare Supply Chain with UDI

      The FDA’s 2013 Unique Device Identification (UDI) Rule sets specific requirements for medical device labeling to improve traceability and patient safety.
      Beth Wells, Senior Director, Community Engagement, Healthcare, GS1 US 02.08.21

    • Stryker Strikes Back After Pandemic Slump

      Stryker Strikes Back After Pandemic Slump

      Late last year, Stryker announced it would snap up Wright Medical to fortify its position in the trauma and extremities markets.
      Sam Brusco, Associate Editor 11.18.20


    • Large Joint
      Obesity and the Impact on Hip and Knee Implants

      Obesity and the Impact on Hip and Knee Implants

      Obesity causes multiple health issues, and the COVID-19 pandemic is only adding to the problem.
      Maria Shepherd, President and Founder, Medi-Vantage 11.18.20

    • Virtually the Same? The Challenges of Online Conferences

      Virtually the Same? The Challenges of Online Conferences

      Like everyone else on the planet, I’m turning increasingly to virtual solutions to our physical challenges in the midst of a pandemic.
      Dawn A. Lissy, Founder & President, Empirical 11.18.20

    • 13 Mistakes to Avoid in a 510k Submission

      13 Mistakes to Avoid in a 510k Submission

      The FDA 510(k) review process can broadly be divided into two steps—acceptance review and substantive review.
      Samradni Patil, Regulatory Consultant and Writer, Kolabtree 11.18.20


    • Contract Manufacturing
      A Supply Chain Strategy for Pandemic Survival

      A Supply Chain Strategy for Pandemic Survival

      Medical device supply chain managers will likely conclude that 2020 is a year best forgotten.
      Tony Freeman, President, A.S. Freeman Advisors LLC 11.18.20

    • Medical Device Equivalence Requirements Strengthened under the EU MDR

      Medical Device Equivalence Requirements Strengthened under the EU MDR

      This column focuses on the directive under EU 2017/745 on medical devices (MDR), highlighting some of the changes in claiming and demonstrating equivalence.
      Cindy Boyer, Senior Manager, International Regulatory Affairs, MCRA LLC 11.18.20

    • Solid Footing During Shaky Times: Current Compliance Considerations

      Solid Footing During Shaky Times: Current Compliance Considerations

      The changes and challenges wrought by COVID-19 have significantly impacted the medtech industry.
      Bryan Brosseau, Founder and Principal Consultant, Brosseau Consulting LLC 11.18.20


    • A Wrinkle in the COVID-19 Financial Recovery

      A Wrinkle in the COVID-19 Financial Recovery

      A British Journal of Surgery study projected the global pandemic would postpone or outright cancel 6.3 million orthopedic procedures.
      Michael Barbella, Managing Editor 09.15.20

    • Research & Development
      Trends for Orthopedic Contract R&D and Manufacturing

      Trends for Orthopedic Contract R&D and Manufacturing

      Over the past 10 years, medtech manufacturers from startups to giants have grown their levels of outsourcing to contract R&D and manufacturing partners.
      Maria Shepherd, President and Founder, Medi-Vantage 09.15.20

    • Self-Care in Business: Four Ways to Extend the Peace of Home to the Workplace

      Self-Care in Business: Four Ways to Extend the Peace of Home to the Workplace

      Like so many small business owners, the lines between work and home often blur in the Lissy household.
      Dawn A. Lissy, Founder & President, Empirical 09.15.20


    Trending
    • FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    • Mini MRI For Hand And Wrist Imaging Can Be Used Nearly Anywhere
    • Cementless Hip Implants Are Gradually Losing Their Popularity In Europe
    • OrthoPediatrics Expands Agent Network In Three European Countries
    • Coronavirus Triggers Double-Digit Revenue Dropoff At Smith+Nephew
    Breaking News
    • Lincotek Medical Expands Coatings and Additive Capacity
    • Spinal Elements Relaunches the Luna XD and Orbit Systems
    • Coronavirus Triggers Double-Digit Revenue Dropoff at Smith+Nephew
    • FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    • FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • Instrumentation Innovations: A Review of Instrument Manufacturing
    • The Total Package: Packaging and Sterilization for Orthopedics
    • Helping Nature Take Its Course: A Biologics Breakdown
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preclinical Trial Suggests Fish Hydrolysate Attenuates Neuroinflammation Greater than DHA Alone
    Study Explains Link Between Probiotic Strains and Children’s Immune Health Benefits
    Maypro Launches Brain Heatlh Ingredient NeuroHD
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Benjamin Moore Launches COMMAND
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Plastikos Medical Begins Phase II of Expansion
    Ready Robotics Hires Proven Automation Leaders
    Philips, Disney Join Forces to Reduce Childrens' MRI Anxiety
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Innoforce and dMed Enter Development Collaboration
    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    Four Female Leaders Appointed to Cell & Gene CDMO
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    BizBash Names Unfiltered Experience ‘People's Choice: Best Influencer Event’
    P&G Makes Progress Toward Packaging Circularity in Europe
    Coty Partners with LanzaTech to Introduce Sustainable Ethanol
    Happi

    Latest Breaking News From Happi

    Coty Partners with LanzaTech to Reduce Its Environmental Impact
    Waterless Beauty, Simplified Routines Shape Clean Beauty at Whole Foods
    Redken Updates Packaging, Adds New Products
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Fort Dearborn Company acquires Hammer Packaging
    Ashland announces PSA price hike in North America
    Arrow Systems and Sihl form flexible packaging partnership
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Joa Announces Expandable Absorbent Core Wrap Solution
    Principle Business Enterprises Celebrates 60 Years
    Mann+Hummel Invests in Pamlico Air
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Lincotek Medical Expands Coatings and Additive Capacity
    Spinal Elements Relaunches the Luna XD and Orbit Systems
    Coronavirus Triggers Double-Digit Revenue Dropoff at Smith+Nephew
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login